PTGX

Protagonist Therapeutics (PTGX)

About Protagonist Therapeutics (PTGX)

Protagonist Therapeutics, Inc. a clinical-stage biopharmaceutical company, which engages in discovering and developing peptide-based therapeutic drugs to address unmet medical needs. Its product pipeline includes PTG-300, PTG-200, and PN-943. The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.

Details

Daily high

$41.68

Daily low

$38.91

Price at open

$39.01

52 Week High

$48.89

52 Week Low

$21.43

Market cap

2.5B

Dividend yield

0.00%

Volume

2.4M

Avg. volume

738,113

P/E ratio

15.56

Protagonist Therapeutics News